

3rd International Conference and Exhibition on Cell & Gene Therapy

October 27-29, 2014 Embassy Suites Las Vegas, USA

The application for the SB small stem cell

James Wang

StemBios Technologies, Inc., USA

Small stem cells, such as spore-like cells, blastomere-like stem cells (BLSCs), and very-small embryonic-like stem cells (VSELs) have been described and debated in recent studies, although their multipotency in human tissues has not yet been confirmed. Here, the discovery of adult multipotent stem cells derived from human bone marrow, which is called StemBios (SB) cells is reported. These isolated SB cells are smaller than 6 micron and are DAPI+ and Lgr5+ (Leucine-Rich Repeat Containing G Protein-Coupled Receptor 5). The SB cells and its application will be discussed in this presentation.

Biography

James Wang was the Senior Scientist/Director of MorphoGen Pharmaceuticals which is a pioneer stem cell company focusing on muscle-derived stem cells. Prior to MorphoGen, he was at VitaGen which is a cell-therapy company dedicated to treating fulminant hepatic failure using bioartificial liver devices. He received his PhD in Molecular Biology at Vanderbilt University and completed his Postdoctoral work at The Salk and Burnham Institute in La Jolla, California. Before joining StemBios, he was an Assistant Research Professor at City of Hope Medical Center. Currently, he is a Chief Scientific Officer in StemBios to lead the stem cell research. He is also the co-inventor of several patents and numerous scientific publications.

jwang@stembios.com